The primary goal of the collaboration is joint research into trending and next-generation molecules
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Subscribe To Our Newsletter & Stay Updated